Research programme: anti-infectives - Kemin

Drug Profile

Research programme: anti-infectives - Kemin

Alternative Names: KPE 00001048; KPE 00001125; KPE 01001001; KPE 01001014; KPE00000297; KPE00000313; KPE03003015; KPE03003017; KPE03003028; KPE05001

Latest Information Update: 17 Jan 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Kemin Pharma
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Bacterial infections; Mycoses

Most Recent Events

  • 23 Sep 2008 Preclinical development is ongoing in Belgium
  • 19 Oct 2006 Data presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2006) have been added to the Bacterial Infections pharmacodynamics section
  • 10 Aug 2006 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top